Nasdaq · Biotech stocks database

MSLE — Satellos Bioscience Inc.

MSLE (Satellos Bioscience Inc.) stock: $7.19, $152.5M market cap, $9.8M cash, $142.7M EV, $149.7M fully diluted market cap. Next expected readout: Mar-27. Lead program: SAT-3247 (Duchenne Muscular Dystrophy), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

Satellos Bioscience is a clinical-stage biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases, with its lead small molecule SAT-3247 in development for Duchenne muscular dystrophy.

Source: company website via company website

Share price

$7.19

Market cap

$152.5M

Cash

$9.8M

Enterprise value

$142.7M

Balance sheet

Cash	$9.8M
Debt	$0.0M
Net cash	$9.8M
Enterprise value	$142.7M
Basic shares	15.4M shares
Fully diluted shares	20.8M shares
Fully diluted market cap	$149.7M
Cash per share	$0.63
Quarterly burn	$5.9M
Cash runway	1.7 quarters

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

15.5M

Pre-funded warrants

3.2M

Options

2.2M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

20.8M

Cap table components pending verification.

Price history

Loading MSLE daily closes…

Loading price history…

Next catalyst

SAT-3247 · Now - Nov 22, 2026 Now · Phase 2 · Duchenne Muscular Dystrophy (DMD)

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 22, 2026 Now	SAT-3247	Phase 2	Duchenne Muscular Dystrophy (DMD)	Q4 2026
May 12 - Jun 23 in 6 mo	SAT-3247	Phase 2	Duchenne Muscular Dystrophy; Duchenne; DMD	Q4 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	SAT-3247
Lead indication	Duchenne Muscular Dystrophy
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07287189	Phase 2	Recruiting	Sponsor	MSLE	—	Duchenne Muscular Dystrophy; Duchenne; DMD	Q4 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)
NCT06867107	Phase 2	Enrolling by invitation	Sponsor	MSLE	—	Duchenne Muscular Dystrophy (DMD)	Q4 2026

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Satellos Bioscience, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Vivo Capital	813,666	no change	0.58%	2026-08-14
Sphera Biotech	652,590	+163,383	0.73%	2026-08-14
Stonepine Capital	491,624	+391,624	2.83%	2026-08-17
ADAR1 Capital Management	222,555	no change	0.08%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

MSLE — Satellos Bioscience Inc.

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

MSLE — Satellos Bioscience Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

MSLE — Satellos Bioscience Inc.